Fate Therapeutics (FATE) Revenue (2012 - 2026)

Fate Therapeutics has reported Revenue for 14 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 20.26% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $6.3 million (down 52.64% YoY), and the FY2025 full-year result was $6.6 million, down 51.24% from the prior year.
• Revenue for Q1 2026 stood at $1.3 million, down from $1.4 million in the prior quarter.
• The five-year high for Revenue was $59.0 million in Q1 2023, with the low at $933000.0 in Q2 2023.
• Historically, Revenue has averaged $10.7 million across 5 years, with a median of $1.9 million in 2024.
• The largest YoY upside for Revenue was 625.83% in 2024 against a maximum downside of 96.74% in 2024.
• Fate Therapeutics' Revenue stood at $44.4 million in 2022, then tumbled by 96.22% to $1.7 million in 2023, then grew by 10.98% to $1.9 million in 2024, then declined by 26.4% to $1.4 million in 2025, then retreated by 5.11% to $1.3 million in 2026.
• The last three Revenue figures came in at $1.3 million (Q1 2026), $1.4 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.